JAZZJazz Pharmaceuticals plc

$11B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$838M+39.5% YoY

Gross Profit

$693M82.7% margin

Operating Income

$28M3.4% margin

Net Income

-$53M-6.3% margin

EPS (Diluted)

$-0.86

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

$274M

Free Cash Flow

$266M

Stock-Based Comp.

$53M

Balance Sheet

Total Assets

$12.5B

Total Liabilities

$8.5B

Stockholders' Equity

$3.9B

Cash & Equivalents

$672M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$838M	$601M	+39.5%
Gross Profit	$693M	$559M	+24.0%
Operating Income	$28M	$196M	-85.5%
Net Income	-$53M	$148M	-135.6%

Revenue Segments

Xyrem

$307M38%

Epidiolex/Epidyolex

$160M20%

Xywav

$153M19%

Zepzelca

$72M9%

Defitelio/Defibrotide

$58M7%

Vyxeos

$35M4%

Rylaze/Enrylaze

$21M3%

Sativex

$6M1%

Other Products

$3M0%

Geographic Segments

UNITED STATES

$757M90%

Europe

$71M8%

Other Countries

$10M1%

JAZZ Q3 2021 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena